AgeneBio, founded by Johns Hopkins investigator Michela Gallagher, says the numbers in a midstage study back up its case that its drug works against Alzheimer’s–a story that the company hopes will deliver the support needed to pursue a Phase III study.

…read more

Source: AgeneBio scouts deals and dollars ahead of Alzheimer’s PhIII


0 No comments